<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045097</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000256355</org_study_id>
    <secondary_id>NCI-02-C-0229</secondary_id>
    <secondary_id>NCI-5791</secondary_id>
    <nct_id>NCT00045097</nct_id>
    <nct_alias>NCT00040079</nct_alias>
  </id_info>
  <brief_title>Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Clinical Trial Of BMS-247550 (NSC 710428), An Epothilone B Analog, In Patients With Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with&#xD;
      locally advanced or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine any antitumor activity of ixabepilone, in terms of objective response rate, in&#xD;
           patients with incurable, locally advanced or metastatic breast cancer.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior taxane&#xD;
      therapy (yes vs no).&#xD;
&#xD;
      Patients (with or without prior taxane exposure) receive ixabepilone IV over 1 hour on days&#xD;
      1-5. An additional cohort of 37 patients who have received prior taxane therapy are then&#xD;
      accrued to receive ixabepilone IV over 1 hour on days 1-3 at a higher starting dose. For all&#xD;
      patients, courses repeat every 3 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients who receive more than 6 courses with satisfactory response may be treated&#xD;
      every 4-5 weeks.&#xD;
&#xD;
      Patients removed for unacceptable toxicty are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 105 patients (at least 74 with and 21 without prior taxane&#xD;
      exposure) will be accrued for this study within 26 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumor activity as measured by CT scans and bone scans at baseline and every other course</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ixabepilone toxicity as measured by lab studies at baseline and after every course</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor tubulin polymerization and p53 expression from biopsy specimens and cDNA microarray testing at baseline and prior to course 2.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotoxicity assessment as measured by Semmes-Weinstein monofilament, sharpened Rombrog, one-legged stance, Jebsen Test of hand function, the grooved pef board , and subjective questionnaires at baseline and prior to every other course</measure>
  </secondary_outcome>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed* adenocarcinoma of the breast&#xD;
&#xD;
               -  Incurable, locally advanced or metastatic disease&#xD;
&#xD;
               -  Primarily stage IV disease, but some inoperable stage III disease may be eligible&#xD;
                  (e.g., a patient with T4 and/or N2-3 disease who cannot receive doxorubicin or&#xD;
                  who has already received other therapy) NOTE: *Patients with no available tissue&#xD;
                  for histologic confirmation but who have documentation of breast surgery and&#xD;
                  prior chemotherapy are eligible upon approval of the principal investigator&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No evidence of CNS metastases by brain MRI or contrast head CT scan&#xD;
&#xD;
               -  CNS metastases controlled by radiotherapy or surgical resection at least 6 months&#xD;
                  prior to study enrollment are allowed&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female or male&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count at least 1,200/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if there&#xD;
             is clinical evidence of Gilbert's disease)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance greater than 40 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No poor medical risk due to other nonmalignant systemic disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No sensory, motor, or cranial neuropathy or neuropathic pain grade 2 or greater&#xD;
             (unless neuropathy is clearly due to underlying breast cancer)&#xD;
&#xD;
          -  No other concurrent serious medical illness&#xD;
&#xD;
          -  No prior severe hypersensitivity reactions to agents containing Cremophor EL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior filgrastim (G-CSF), pegfilgrastim, or thrombopoietin (or&#xD;
             other platelet growth factors)&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy for breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 2 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior craniospinal radiation&#xD;
&#xD;
          -  No prior total body irradiation&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent cytochrome p450 3A4 inhibitors, including any of the following:&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Delaviridine&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Amprenavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Lopinavir&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole (&gt; 200 mg/day)&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
          -  Concurrent bisphosphonates for bone metastases allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra M. Swain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Care Associates</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, Chow CK, Steinberg SM, Yang SX, Swain SM. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007 Aug 10;25(23):3421-7. Epub 2007 Jul 2.</citation>
    <PMID>17606971</PMID>
  </results_reference>
  <results_reference>
    <citation>Low J, Croarkin E, Parks R, et al.: Assessment of neurotoxicity in patients receiving BMS-247550 for metastatic breast cancer. [Abstract] Breast Cancer Research and Treatment 85.2: A-358, 2004. Also available online. Last accessed April 22, 2004.</citation>
  </results_reference>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

